Choosing the best biotech stocks can sometimes feel like a gamble. Trying to figure out which company’s drug candidates are likely to work, or if your ownership stake will be oiled as the company tries to secure funding to continue the trial, it can often feel like a guessing game.
That’s why it’s a good idea to buy a small stake in many companies to reduce the risk that any company will have a full bust. With that in mind, we can evaluate the opportunities for science, business and the three best biotech stocks to buy right now.
Image Source: Getty Images.
Biotech
The potential coronavirus vaccine he is working on after reporting extremely positive Phase 3 results on Monday Pfizer (NYSE: PFE), Biotech (Nasdaq: BNTX) It may be known forever for the partnership. The results show that the vaccine candidate is 90% effective and will be ready to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) when the required two months of data is completed, which should be in the third week of November.
A large unknown residue: No one in the trial developed a serious case of COVID-19, so it was not clear how well the vaccine prevents bad consequences such as hospitalization and death. Still, Biotex has demonstrated its ability to use messenger ribonucleic acid (mRNA) to treat persistent diseases. With its stock all-time high, the company has distinguished itself as a leader in cutting edge age-based drugs that deserve a place in the portfolio of any biotech investor.
Querwake
Like Bayonet Tech, this German biotech has recently announced positive results using the mRNA vaccine candidate to fight coronavirus. Unlike bioentech, QuerwakeNo. (Nasdaq: CVAC) The candidate is only in the first phase 1 trials, so he has to go a long way before showing effectiveness in humans. But there is support for the company to get there.
Its high-profile funds include the German government, the founder of a software company S.A.P. (NYSE: SAP), Ally Lily (NYSE: LLY), And the Bill & Melinda Gates Foundation.
Tesla (Nasdaq: TSLA) And its CEO, Elon Musk, is also a partner in this effort. Carmaker manufactures RNA bioreactors that stimulate and streamline the company’s vaccine production. After positive Phase 1 data, the vaccine will now go through Phase 2/3 testing, during which 36,000 participants are expected to register.
CRISPR Therapeutic
CRISPR Therapeutic (Nasdaq: CRSP) Is one of a handful of public companies offering the benefit of a “clip-and-paste” function associated with bacterial immune responses to edit genes as a treatment for disease. Such bacteria “paste” viruses into “clip” parts of DNA and their own genes so that they can identify future attackers. Scientists can use this function to alter the genetic sequence of organisms and to alter the function of cells. This is especially helpful for diseases with a single gene defect such as single cell anemia and cystic fibrosis.
So far, management has used this approach to target cancer and blood disorders, with positive results in initial tests. Science has proven, and with a founder who recently won the Nobel Prize, funding for research is unlikely to be a problem.
With a market cap of just billions of dollars, once the method proves to be safe in humans, CRISPR therapeutics could become one of the most important disease fighting companies out there in the next decade. That said, biotech is likely to be volatile at any early stage. Buying shares of CRISPR puts a reliance on gene-acquisition technology, which can take years to prove itself. Investors should keep this timeline in mind when buying.
